The expression of BRD4 is significantly higher in clinical ovarian cancer tissues than in non-malignant control tissues, whereas the levels of BRD2 and BRD3 do not significantly vary between malignant and non-malignant tissues. Here, BRD2 is linked to ovarian cancer.